XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

– Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study – Preliminary efficacy data highlight XC001 potential for patients with refractory angina with no other treatment options – Treatment … [Read more…]

Viseon Inc. Announces Milestone of 1,000 U.S. Clinical Cases with MaxView® Intraoperative Realtime Spinal Imaging Technology

IRVINE, Calif.–(BUSINESS WIRE)–Today Viseon Inc. announced that it recently achieved over 1,000 U.S. Minimally Invasive Spine Surgery cases utilizing the Viseon MaxView Imaging Platform. MaxView is a state-of-the-art intraoperative imaging technology that enables a highly magnified unobstructed view of the surgical corridor and critical anatomy projected in real time onto operating room flat panel displays … [Read more…]

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

New funding will support ongoing clinical development of lead candidate, SBT101 for adrenomyeloneuropathy (AMN) Phase 1/2 study initiation of SBT101 expected in the second half of 2022 Pipeline development to continue, focused on spinal cord-related disorders PHILADELPHIA–(BUSINESS WIRE)–SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological … [Read more…]

NanoString to Webcast Presentation from the UBS 2022 Global Healthcare Conference

SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 2022 UBS Global Healthcare Conference. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, May 25, 2022, at 9:15 am ET. … [Read more…]

Signature Bank Launches New National Business Line With Appointment of Healthcare Banking and Finance Team

Nine Seasoned Banking Professionals Comprise New Private Client Banking Team to Serve Healthcare Industry NEW YORK–(BUSINESS WIRE)–Signature Bank (Nasdaq: SBNY), a New York-based, full-service commercial bank, announced today the launch of a new business line with the appointment of a nine-person Healthcare Banking and Finance (HBF) team. The new private client banking team will provide … [Read more…]

Global Senolytic Drugs Market Analysis/Research Report 2022: Focus on FOXO4-related Peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Senolytic Drugs Market, By Type (FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, Others), By Application, By Distribution Channel, By Region, Competition Forecast and Opportunities, 2017-2027” report has been added to ResearchAndMarkets.com’s offering. The global senolytic drugs market is expected to grow at a significant rate during … [Read more…]

Cell Based Assay & High Content Screening Markets 2022-2026: Post Pandemic Conditions Bode Well for Cell Based Assay and High Content Screening Markets – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Based Assay & High Content Screening Markets 2022 to 2026: Forecasts by User and Product. With Executive and Consultant Guides. including Customized Forecasting and Analysis. “ report has been added to ResearchAndMarkets.com’s offering. Cell Based Assays are a mainstay of drug development and scientific research, and now, post pandemic, research activity is … [Read more…]

Patient Centricity, AI-Powered Insights and Diversity in Clinical Trials Among Key Topics at Medidata NEXT London

Medidata experts to be joined by thought leaders from Moderna, Roche, Bayer, Lundbeck, Parexel, Datavant and UK’s National Institute for Health and Care Research (NIHR) LONDON–(BUSINESS WIRE)–Medidata, a Dassault Systèmes company, will gather industry experts across drug development, clinical research and operations, data management and digital health to address the industry’s most pressing challenges at … [Read more…]

New World Group’s Humansa Announces New Strategic Focus

First-class integrated health and wellness services that capture the growing demand in Hong Kong and other cities in the Greater Bay Area HONG KONG–(BUSINESS WIRE)–Humansa, a healthcare organization under the New World Group, today announced its new strategic focus as a premium and comprehensive provider of preventative healthcare and wellness services to capture emerging market … [Read more…]

Generation Launches $1.7 Billion Sustainable Solutions Fund IV to Invest in Growth-Stage Companies Driving the Sustainable Future

Generation’s fourth and largest Growth Equity fund invests in teams delivering responsible innovation at scale and accelerating sustainable industry transitions LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Generation Investment Management, a pure-play sustainable investment manager with over $36 billion of assets under management, today announced the launch of its $1.7 billion Sustainable Solutions Fund IV. The new fund … [Read more…]